methylxanthine

07/01/2019 - "We aimed to describe the current methylxanthine use for acute asthma and to determine factors related to its use in the ED. "
07/01/2019 - "Methylxanthine use for acute asthma in the emergency department in Japan: a multicenter observational study."
01/01/1987 - "[Methylxanthine preparations in the therapy of bronchial asthma]."
10/01/2023 - "Beneficial effects of coffee for subjects with asthma, primarily the effect of methylxanthine components, have long been described. "
12/01/2021 - "The second-line treatment options for acute asthma include parenteral β2-agonists, methylxanthine and magnesium sulphate (MgSO4). "

01/01/1992 - "The present study was designed to assess effectiveness and safety and the proarrhythmic effects of two methylxanthine derivatives, doxofylline and aminophylline, in the management of chronic obstructive pulmonary disease associated with cardiac rhythm disturbances. "
11/14/1986 - "Pharmacotherapy of obstructive lung disease has improved both quantitatively and qualitatively in recent decades: quantitatively with improvements in adrenergic and methylxanthine drugs and qualitatively with the addition of new classes of drugs, such as steroids, cromolyn, and, most recently, anticholinergic agents. "

11/01/1998 - "Substantial improvements in tumor oxygenation and perfusion were observed after administration of the methylxanthine derivatives. "
11/01/1998 - "Thus, while the methylxanthine derivatives caused an increased average tumor perfusion, there is evidence suggesting that a redistribution of tumor blood flow occurs which may amplify preexisting heterogeneity. "
11/01/1998 - "The use of methylxanthine derivatives has been postulated as a means of increasing tumor perfusion and thus ameliorating tumor hypoxia. "
11/01/1998 - "Regional perfusion and oxygenation of tumors upon methylxanthine derivative administration."
05/30/1990 - "Methylxanthine consumption and the risk of ovarian malignancy."

03/01/2016 - "The potential of methylxanthine-based therapies in pediatric respiratory tract diseases."
01/01/2022 - "Theophylline, a methylxanthine drug, has been used as a therapy for respiratory diseases. "
12/01/2020 - "Theophylline is a methylxanthine drug used in therapy for respiratory diseases. "
01/01/2023 - "Theophylline is a methylxanthine derivate used in the treatment of respiratory diseases with only a few randomized control trials or case reports describing pain improvement in low CSF pressure states or spontaneous intracranial hypotension (SIH). "
08/01/2019 - "Since several evidences highlighted the importance of a hierarchical model of differentiation among cancer cells, closely related to resistance mechanisms and tumor relapse, we investigated the effects of theophylline (Theo), a methylxanthine commonly used in treatment of respiratory diseases, on melanoma cells with different degree of differentiation, including patient-derived melanoma-initiating cells. "

09/19/1996 - "Methylxanthine (i.t.)-induced behavior was partially inhibited by antagonists of receptors for pain neurotransmitters. "
04/12/2010 - "It produces antinociception in several preclinical models of pain, and these actions are blocked by methylxanthine adenosine receptor antagonists which implicates adenosine it its actions. "
08/01/2008 - "It produces antinociception in several animal models of pain, and this effect is blocked by methylxanthine adenosine receptor antagonists which implicates adenosine it its actions. "
01/01/2023 - "Theophylline is a methylxanthine derivate used in the treatment of respiratory diseases with only a few randomized control trials or case reports describing pain improvement in low CSF pressure states or spontaneous intracranial hypotension (SIH). "
04/01/2003 - "Release of adenosine from both spinal and peripheral compartments has inhibitory effects on pain transmission, as methylxanthine adenosine receptor antagonists reduce analgesia produced by agents which augment extracellular levels of adenosine spinally (morphine, 5-HT, substance P, AK inhibitors) and peripherally (AK inhibitors, AD inhibitors). "